Optimal management of inflammatory bowel disease during the COVID-19 epidemic

VernacularTitle:新型冠状病毒肺炎流行期间的炎症性肠病优化管理
Author: Yicheng JIAN ¹ ; Zhihua RAN ¹
Author Information

1. 上海健康医学院附属周浦医院消化科，上海　201318
Publication Type:Journal Article
Keywords: Corona virus disease-19; Inflammatory bowel disease; Treatment; Management
From: Chinese Journal of Inflammatory Bowel Diseases 2024;08(1):91-94
CountryChina
Language:Chinese
Abstract: This review aims to summarize the current evidence on the risk and impact of coronavirus disease 2019 (COVID-19) in patients with inflammatory bowel disease (IBD), and to discuss optimal management of IBD during this outbreak. IBD patients did not have a higher incidence of COVID-19 or more severe disease progression. Multiple factors are associated with an increased risk of COVID-19 infection, increased hospitalization rate, and increased risk of severe COVID-19. Treatment of IBD is not associated with more severe COVID-19, and the association of 5-aminosalicylic acid and thiopurine with increased risk of COVID-19 is controversial. Treatment regiments for IBD patients with different categories and levels of disease need to be adjusted during the epidemic. COVID-19 vaccine is effective and safe for patients with IBD.